@article{2e7c4e1648d74166bc27c71df5494686,
title = "Designed PKC-targeting bryostatin analogs modulate innate immunity and neuroinflammation",
abstract = "Bryostatin-1, a brain-penetrant natural compound, was previously shown to attenuate neuroinflammation by targeting innate immunity but has tolerability constraints. Abramson et al. identified synthetic analogs (bryologs) that similarly modulate innate immunity, including a lead bryolog with tolerability advantages and equivalent efficacy, creating a platform for drug development in neuroinflammation.",
keywords = "bryolog, bryostatin, EAE, innate immunity, microglia, multiple sclerosis, neuroinflammation, PKC, prostratin",
author = "Efrat Abramson and Clayton Hardman and Shimizu, {Akira J.} and Soonmyung Hwang and Hester, {Lynda D} and Snyder, {Solomon H.} and Wender, {Paul A.} and Kim, {Paul M.} and Michael Kornberg",
note = "Funding Information: This work was supported by grants from the NIH ( CA31845 to P.A.W., P50 DA044123 to S.H.S.), Conrad N. Hilton Foundation (Marilyn Hilton Bridging Award for Physician Scientists to M.D.K.), and Race to Erase MS (Young Investigator Award to M.D.K.). The authors thank B. Paul, M. Smith, A. Snowman, L. Albacarys, S. McTeer, and P. Calabresi for advice and support. Graphical abstract was produced with Biorender.com . Funding Information: This work was supported by grants from the NIH (CA31845 to P.A.W. P50 DA044123 to S.H.S.), Conrad N. Hilton Foundation (Marilyn Hilton Bridging Award for Physician Scientists to M.D.K.), and Race to Erase MS (Young Investigator Award to M.D.K.). The authors thank B. Paul, M. Smith, A. Snowman, L. Albacarys, S. McTeer, and P. Calabresi for advice and support. Graphical abstract was produced with Biorender.com. Conceptualization, P.A.W. P.M.K. and M.D.K.; Methodology, P.A.W. P.M.K. and M.D.K.; Investigation, E.A. C.H. A.J.S. S.H. L.D.H. P.M.K. and M.D.K.; Formal analysis, E.A. C.H. A.J.S. P.M.K. and M.D.K.; Resources, P.A.W. and S.H.S.; Writing ? Original Draft, P.M.K. and M.D.K.; Writing ? Review and Editing, E.A. C.H. P.A.W. P.M.K. and M.D.K.; Funding Acquisition, S.H.S. P.A.W. and M.D.K. Johns Hopkins University and Stanford University have filed patent applications on this and related technology. Stanford University patent applications have been licensed by Neurotrope BioScience for the treatment of neurological disorders and by Bryologyx Inc. for use in HIV/AIDS eradication and cancer immunotherapy. P.A.W. is an advisor to both companies and a cofounder of the latter. M.D.K. has received consulting fees from OptumRx and Biogen Idec. The remaining authors declare no competing interests.",
year = "2021",
doi = "10.1016/j.chembiol.2020.12.015",
language = "English (US)",
journal = "Cell Chemical Biology",
issn = "2451-9448",
publisher = "Elsevier Inc.",
}